A standardized approach to acquiring amyloid PET images increases their value as disease and drug response biomarkers. Most ¹⁸F PET amyloid brain scans often are assessed only visually (per regulatory labels), with a binary decision indicating the presence or absence of Alzheimer disease amyloid pathology. Minimizing technical variance allows precise, quantitative SUV ratios (SUVRs) for early detection of β-amyloid plaques and allows the effectiveness of antiamyloid treatments to be assessed with serial studies. Methods: The Quantitative Imaging Biomarkers Alliance amyloid PET biomarker committee developed and validated a profile to characterize and reduce the variability of SUVRs, increasing statistical power for these assessments. Results: On achieving conformance, sites can justify a claim that brain amyloid burden reflected by the SUVR is measurable to a within-subject coefficient of variation of no more than 1.94% when the same radiopharmaceutical, scanner, acquisition, and analysis protocols are used. Conclusion: This overview explains the claim, requirements, barriers, and potential future developments of the profile to achieve precision in clinical and research amyloid PET imaging.

获取淀粉样蛋白 PET 图像的标准化方法增加了其作为疾病和药物反应生物标志物的价值。大多数¹⁸ F PET 淀粉样蛋白脑部扫描通常仅通过视觉评估（根据监管标签），并通过二元决定表明是否存在阿尔茨海默病淀粉样蛋白病理。最大限度地减少技术差异可以实现精确、定量的 SUV 比率 (SUVR)，以便早期检测 β-淀粉样蛋白斑块，并允许通过系列研究评估抗淀粉样蛋白治疗的有效性。方法：定量成像生物标志物联盟淀粉样蛋白 PET 生物标志物委员会开发并验证了一个概况，以表征和减少 SUVR 的变异性，从而提高这些评估的统计功效。结果：在达到一致性时，站点可以证明这样一种说法：当使用相同的放射性药物、扫描仪、采集和分析方案时，SUVR 反映的脑淀粉样蛋白负荷可测量到受试者内变异系数不超过 1.94%。结论：本概述解释了在临床和研究淀粉样蛋白 PET 成像中实现精确性的概况的主张、要求、障碍和潜在的未来发展。